Literature DB >> 12711008

Characterisation of gene expression patterns in 22RV1 cells for determination of environmental androgenic/antiandrogenic compounds.

A Hartel1, A Didier, M W Pfaffl, Heinrich H D Meyer.   

Abstract

Alteration of androgen receptor function due to hormonally active compounds in the environment, may be responsible for impaired reproductive function in aquatic wildlife. Based on human prostate carcinoma 22RV1 cells, a cell culture expression system was established to test effects of putative androgenic/antiandrogenic compounds on endogenous gene expression. 22RV1 cells were shown to express human androgen receptor, but not human progestin (hPR) or human oestrogen receptor (hER) alpha and beta. Six androgen-regulated genes (ARGs) were chosen to determine androgenic/antiandrogenic action using highly sensitive real-time RT-PCR. Results showed that gene expression is altered in a time-dependent manner. After stimulation of cells by DHT (10nM), synthetic androgen R1881 (1 nM), or organic pesticides (difenoconazole, fentinacetate, tetramethrin) TMPRSS2 mRNA expression was down-regulated by the factor 0.6 after 24h of DHT treatment. Similar results were obtained when cells were assayed for mRNA expression of PSA after fentinacetate and R1881 stimulation. In contrast, TMPRSS2 expression was up-regulated by the factor 0.9 when cells were stimulated by tetramethrin. Final goal of the work is a sensitive determination of differential gene expression by different compounds under study, achievement of substance-specific expression patterns and function related analysis of potential androgens/antiandrogens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12711008     DOI: 10.1016/s0960-0760(03)00033-5

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  8 in total

1.  ATBF1 inhibits estrogen receptor (ER) function by selectively competing with AIB1 for binding to the ER in ER-positive breast cancer cells.

Authors:  Xue-Yuan Dong; Xiaodong Sun; Peng Guo; Qunna Li; Masakiyo Sasahara; Yoko Ishii; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

2.  Estrogen up-regulates ATBF1 transcription but causes its protein degradation in estrogen receptor-alpha-positive breast cancer cells.

Authors:  Xue-Yuan Dong; Peng Guo; Xiaodong Sun; Qunna Li; Jin-Tang Dong
Journal:  J Biol Chem       Date:  2011-03-02       Impact factor: 5.157

3.  Regulation of androgen-responsive transcription by the chromatin remodeling factor CHD8.

Authors:  Tushar Menon; Joel A Yates; Daniel A Bochar
Journal:  Mol Endocrinol       Date:  2010-03-22

4.  Lobaric acid prevents the adverse effects of tetramethrin on the estrous cycle of female albino Wistar rats.

Authors:  Ha Thi Nguyen; Haritha Polimati; Satya Sowbhagya Priya Annam; Emmanuel Okello; Quynh-Mai Thai; Thien-Y Vu; Vinay Bharadwaj Tatipamula
Journal:  PLoS One       Date:  2022-07-01       Impact factor: 3.752

5.  p21-Activated kinase 6 (PAK6) inhibits prostate cancer growth via phosphorylation of androgen receptor and tumorigenic E3 ligase murine double minute-2 (Mdm2).

Authors:  Tong Liu; Yang Li; Hui Gu; Ge Zhu; Jiabin Li; Liu Cao; Feng Li
Journal:  J Biol Chem       Date:  2012-11-06       Impact factor: 5.157

6.  Sulfur inhibits the growth of androgen-independent prostate cancer in vivo.

Authors:  Fei Duan; Yuhua Li; Liangkang Chen; Xiaoyu Zhou; Jianxing Chen; Hailin Chen; Runsheng Li
Journal:  Oncol Lett       Date:  2014-11-11       Impact factor: 2.967

7.  Prussian blue nanoparticles as nanocargoes for delivering DNA drugs to cancer cells.

Authors:  Shao-Jen Wang; Chun-Sheng Chen; Lin-Chi Chen
Journal:  Sci Technol Adv Mater       Date:  2013-08-06       Impact factor: 8.090

8.  Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer.

Authors:  Yoshinori Matsuda; Shintaro Narita; Taketoshi Nara; Huang Mingguo; Hiromi Sato; Atsushi Koizumi; Sohei Kanda; Kazuyuki Numakura; Mitsuru Saito; Takamitsu Inoue; Yuko Hiroshima; Hiroshi Nanjo; Shigeru Satoh; Norihiko Tsuchiya; Tomonori Habuchi
Journal:  BMC Cancer       Date:  2020-04-15       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.